Pulmonary Embolism Drugs Market Trends

Growth Drivers

• Growing Prevalence of Bone Fractures - Bone fracture is one of the major reasons to cause of pulmonary embolism since during bone injury, fat around the muscle turns into broken blood vessels. When these symptoms are developed owing to a lack of medical attention, they turn into embolism syndrome. For instance, it was anticipated that nearly 1 million individuals suffer from bone fractures annually.

• Rising Awareness of Pulmonary Embolism Across the Globe - In modern times, owing to the developing medical technology and the launch of new innovative diagnostic devices has spurred awareness of the early diagnosis of pulmonary embolism which is anticipated to hike the market growth over the forecast period. It was estimated that around 35% of people lose their lives before getting any sort of diagnosis and treatment.

• Increasing Prevalence of Pulmonary Embolism (PE) - The prevalence of pulmonary embolism is so high that it is third behind heart attack and stroke. For instance, approximately 300,000 people lose their lives every year in the United States.

• Growing Incidences of Heart Failure to Boost Market Growth - Heart failure is also considered to be one of the major causes of pulmonary embolism. For instance, it was estimated that approximately 6 million Americans aged above 20 have heart failure while 900,000 new cases of heart failure are diagnosed every year in the American region.  

Challenges

• Side Effects of Pulmonary Embolism Drugs - The possibility of side effects can be quite higher owing to the consumption of pulmonary embolism drugs such as chest pain, shortness of breath, anxiety, dizziness, fainting, and others. Hence, such a higher number of side effects owing to the consumption of these drugs was projected to hamper the growth of the market over the forecast period.
• Higher Possibility of Blood Clotting
• Lack of Awareness regarding Pulmonary Embolism Drugs